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Abstract Patients with Gorham-Stout disease (GSD) have lymphatic vessels in their bones and
their bones gradually disappear. Here, we report that mice that overexpress VEGF-C in bone
exhibit a phenotype that resembles GSD. To drive VEGF-C expression in bone, we generated Osx-
tTA;TetO-Vegfc double-transgenic mice. In contrast to Osx-tTA mice, Osx-tTA;TetO-Vegfc mice
developed lymphatics in their bones. We found that inhibition of VEGFR3, but not VEGFR2,
prevented the formation of bone lymphatics in Osx-tTA;TetO-Vegfc mice. Radiological and
histological analysis revealed that bones from Osx-tTA;TetO-Vegfc mice were more porous and had
more osteoclasts than bones from Osx-tTA mice. Importantly, we found that bone loss in Osx-tTA;
TetO-Vegfc mice could be attenuated by an osteoclast inhibitor. We also discovered that the
mutant phenotype of Osx-tTA;TetO-Vegfc mice could be reversed by inhibiting the expression of
VEGF-C. Taken together, our results indicate that expression of VEGF-C in bone is sufficient to
induce the pathologic hallmarks of GSD in mice.
DOI: https://doi.org/10.7554/eLife.34323.001
Introduction
Lymphatic vessels perform several essential functions in the body. Lymphatic vessels absorb intesti-
nal lipids, transport immune cells, and return fluid and macromolecules to the blood vasculature
(Witte et al., 1997; Zheng et al., 2014). Most soft tissues in the body have lymphatic vessels
(Witte et al., 1997). In contrast, hard tissues such as enamel, dentin, and bone do not have lym-
phatic vessels. Gorham-Stout disease (GSD) is a sporadic disease that is characterized by the pres-
ence of lymphatics in bone and bone loss (Gorham and Stout, 1955; Dellinger et al., 2014). J.B.S.
Jackson is credited with publishing the first case of GSD, which appeared in the Boston Medical and
Surgical Journal in 1838 (Jackson, 1838). In his paper entitled ‘A Boneless Arm’, Jackson described
a patient whose humerus had completely disappeared (Jackson, 1838). Over 100 years later, Gor-
ham and colleagues published a paper that described two additional cases of massive bone loss
(Gorham et al., 1954). They were able to analyze multiple affected bones from one patient and
found that the bones were filled with irregular vessels (Gorham et al., 1954). This interesting obser-
vation inspired Gorham and Stout to review additional cases of massive bone loss. Over several
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years, Gorham and Stout were able to acquire biopsy specimens from seven patients seen by other
physicians (Gorham and Stout, 1955). They observed abnormal vessels in each of the bone biopsy
specimens they analyzed (Gorham and Stout, 1955). This finding led Gorham and Stout to report
that massive bone loss is associated with the growth of vessels in bone (Gorham and Stout, 1955).
It is now known that bones from GSD patients are filled with lymphatic vessels (Lala et al., 2013;
Ozeki et al., 2016; Edwards et al., 2008).
Since Gorham and Stout’s landmark publication, more than 300 cases of GSD have been
described (Dellinger et al., 2014). These case reports have further defined the clinical characteristics
of the disease. GSD affects males and females equally and is most commonly diagnosed in children
and young adults (Dellinger et al., 2014). The course of this disease is often unpredictable. In some
patients, the disease progresses slowly over a period of years, whereas in others, it progresses rap-
idly over a period of months (Dellinger et al., 2014). In severe cases, the disease progresses until
entire bones are lost and replaced by fibrous tissue. The disease is reported to arrest and stabilize
after a variable period of activity. Importantly, affected bones do not regenerate after the disease
has arrested (Dellinger et al., 2014). Although GSD can affect any bone in the body, it most fre-
quently affects the ribs and vertebrae (Dellinger et al., 2014; Lala et al., 2013). Unfortunately, tho-
racic involvement is associated with a poor prognosis because these patients tend to develop
chylothorax, a complication that can cause respiratory distress, failure, and death (Lala et al., 2013;
Ludwig et al., 2016). Despite advances in the understanding of the clinical features of the disease,
the cause of GSD remains unknown and there are no standard treatments for this disease.
Vascular endothelial growth factor-C (VEGF-C) is the principle driver of lymphangiogenesis. Full-
length VEGF-C undergoes proteolytic processing, which increases its affinity for VEGFR2 and
VEGFR3 (Joukov et al., 1996; Joukov et al., 1997). Studies with genetically engineered mice have
revealed that loss of VEGF-C impairs the development of the lymphatic vasculature. Mice that
completely lack VEGF-C do not form lymphatics, whereas mice that lack a single copy of the VEGF-C
gene develop fewer lymphatics than wildtype mice (Dellinger et al., 2007; Karkkainen et al.,
2004). Conversely, tissue-specific overexpression of VEGF-C has been shown to induce lymphangio-
genesis in the pancreas (Mandriota et al., 2001), lungs (Yao et al., 2014), and skin (Jeltsch et al.,
1997; Lohela et al., 2008). In the present study, we characterize the effect of VEGF-C overexpres-
sion in bone on lymphatics and bone structure.
Results
VEGF-C induces the formation of bone lymphatics
Osterix (Osx) is a transcription factor expressed by chondrocytes, osteocytes, and osteoblasts
(Zhou et al., 2010). A transgenic mouse line was previously created in which the expression of a tet-
racycline transactivator (tTA) cassette was placed under the control of the Osx promoter
(Rodda and McMahon, 2006). This transgenic mouse line also has a TetO-Cre::GFP cassette located
immediately downstream of the tTA cassette (Rodda and McMahon, 2006). To identify cell types
that display tTA activity in Osx-tTA-TetO-Cre::GFP mice, we characterized the expression pattern of
the Cre::GFP fusion protein with an anti-green fluorescent protein (GFP) antibody. GFP was
expressed by chondrocytes, osteocytes, and osteoblasts (Figure 1—figure supplement 1). GFP was
not expressed by cells in the kidney, liver, lung, pancreas, skeletal muscle, or spleen (Figure 1—fig-
ure supplement 1). These data show that tTA activity in Osx-tTA-TetO-Cre::GFP mice (herein
referred to as Osx-tTA) is restricted to bone.
To induce VEGF-C expression in bone, we bred Osx-tTA transgenic mice with TetO-Vegfc trans-
genic mice (Figure 1—figure supplement 2). No viable Osx-tTA;TetO-Vegfc offspring were
obtained from these crosses. To determine whether Osx-tTA;TetO-Vegfc mice died during embry-
onic development, we analyzed mice on embryonic day (E)12.5, E14.5, and E16.5. Osx-tTA;TetO-
Vegfc mice were grossly indistinguishable from control littermates on E12.5. However, Osx-tTA;
TetO-Vegfc mice were severely edematous and displayed enlarged lymphatics on E14.5. All Osx-
tTA;TetO-Vegfc mice were in the process of being resorbed on E16.5 (Figure 1—figure supplement
2). These data indicate that VEGF-C expression by bone cells during embryonic development has a
lethal effect. To overcome this lethal effect, we bred Osx-tTA mice with TetO-Vegfc mice and placed
mice on doxycycline water from E0.5 to E18.5. Mice were then placed on normal water to induce
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the expression of VEGF-C during postnatal development. To determine whether VEGF-C expression
by bone cells induced the formation of bone lymphatics, we stained femurs from 21, 28, and 35-day-
old Osx-tTA and Osx-tTA;TetO-Vegfc mice with an anti-podoplanin antibody. Lymphatic vessels
were not present in femurs from 21, 28, or 35-day-old Osx-tTA mice. Similarly, lymphatic vessels
were not present in femurs from 21-day-old Osx-tTA;TetO-Vegfc mice. In contrast, lymphatic vessels
were present in femurs from 28-day-old Ox-tTA;TetO-Vegfc mice. However, lymphatic vessels were
restricted to cortical bone (the dense outer shell of bone). In 35-day-old Osx-tTA;TetO-Vegfc mice,
lymphatic vessels were located in cortical bone, trabecular bone, and the marrow cavity (Figure 1).
Tibias and ribs from 35-day-old Osx-tTA;TetO-Vegfc mice also had lymphatics (Figure 1—figure
supplement 3). These vessels expressed Lyve-1, another marker of lymphatic endothelium (Fig-
ure 1—figure supplement 3). Although 35-day-old Osx-tTA;TetO-Vegfc mice had hyperplastic lym-
phatics in bones, lymphatics in soft tissues (kidney, liver, lungs, and pancreas) appeared normal and
the circulating level of VEGF-C was not elevated (Figure 1—figure supplement 4). These data indi-
cate that expression of VEGF-C in bone induces the formation of bone lymphatics, but not the
growth of lymphatics in distant tissues.
VEGFR3 signaling is required for the formation of bone lymphatics
VEGF-C activates VEGFR2 and VEGFR3 (Joukov et al., 1996). However, VEGF-C is thought to pri-
marily induce lymphangiogenesis by activating VEGFR3 (Veikkola et al., 2001). To determine
whether VEGF-C activation of VEGFR2 or VEGFR3 was required for the formation of bone lym-
phatics, we treated 21-day-old Osx-tTA;TetO-Vegfc mice with vehicle, DC101 (VEGFR2 function-
blocking antibody), or mF4-31C1 (VEGFR3 function-blocking antibody) for 2 weeks. The density of
bone lymphatics was modestly reduced in DC101-treated mice. In contrast, bone lymphatics failed
to form in mF4-31C1-treated mice (Figure 2). These data show that VEGFR3 signaling is required for
the development of bone lymphatics in Osx-tTA;TetO-Vegfc mice.
In contrast to murine VEGF-C, murine VEGF-D only activates VEGFR3 (Baldwin et al., 2001). A
transgenic mouse strain was recently created in which the expression of murine VEGF-D is controlled
by doxycycline (Lammoglia et al., 2016). To determine whether murine VEGF-D could induce the
formation of bone lymphatics, we generated Osx-tTA;TetO-Vegfd mice. Osx-tTA;TetO-Vegfd mice
received doxycycline water from E0.5 to E18.5 and then normal water from E18.5 to postnatal day
(P) 35. Importantly, femurs from Osx-tTA;TetO-Vegfd mice were filled with lymphatic vessels (Fig-
ure 2). These data show that activation of VEGFR3 is sufficient for the formation of bone lymphatics.
Bone loss in Osx-tTA;TetO-Vegfc mice is mediated by osteoclasts
To characterize the effect of VEGF-C expression by bone cells on bone structure, we X-rayed femurs
from 21, 28, and 35-day-old Osx-tTA and Osx-tTA;TetO-Vegfc mice. Femurs from 21-day-old Osx-
tTA;TetO-Vegfc mice appeared normal and were indistinguishable from femurs from Osx-tTA mice
(Figure 3—figure supplement 1). In contrast, femurs from 28- and 35-day-old Osx-tTA;TetO-Vegfc
mice had a moth-eaten appearance (Figure 3—figure supplement 1). The development of this phe-
notype coincided with the formation of lymphatics in cortical bone. To further characterize the struc-
ture of cortical bone, we took mCT images of femurs and ribs from 35-day-old Osx-tTA and Osx-tTA;
TetO-Vegfc mice. This revealed that bones from Osx-tTA;TetO-Vegfc mice were significantly more
porous than bones from Osx-tTA mice (Figure 3). To determine whether the structural defects in
Osx-tTA;TetO-Vegfc bones affected bone strength, we performed a three-point bending assay. The
three-point bending assay revealed that femurs from Osx-tTA;TetO-Vegfc mice were significantly
weaker than femurs from Osx-tTA mice (Figure 3).
Next, we set out to delineate the cause of bone loss in Osx-tTA;TetO-Vegfc mice. To determine
whether lymphatic endothelial cells (LECs) could directly degrade bone, we cultured RAW264.7 cells
(osteoclast precursor cell line) and primary human LECs in separate wells of an osteo-assay surface
plate. The osteo-assay surface plate has a calcium-phosphate coating that mimics bone. After cultur-
ing cells for 72 hr, we observed numerous resorption pits in wells containing differentiated
RAW264.7 cells (osteoclasts), but not in wells containing LECs (Figure 3—figure supplement 2).
This finding suggests that LECs do not directly degrade bone.
Osteoclasts are multi-nucleated cells that degrade bone and display tartrate-resistant acid phos-
phatase (TRAP) activity. To determine whether there was a difference in the number of osteoclasts
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Figure 1. Osx-tTA;TetO-Vegfc mice develop lymphatics in their bones. (A) Schematic of the Tet-Off system used to express VEGF-C in bone.
Doxycycline inhibits the expression of VEGF-C. (B) Schematic showing when mice received normal water and doxycycline water. Osx-tTA and Osx-tTA;
TetO-Vegfc mice received doxycycline water from E0.5 to E18.5 and then normal water from E18.5 to P35. (C–H) Representative images of cortical bone
in Osx-tTA and Osx-tTA;TetO-Vegfc femurs. Sections were stained with an anti-podoplanin antibody. Arrowheads point to podoplanin-positive
osteocytes. Arrows point to podoplanin-positive lymphatics. (I) Graph showing lymphatic vessel index values for cortical bone in P21 (0 ± 0.0; n = 3), P28
Figure 1 continued on next page
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between Osx-tTA and Osx-tTA;TetO-Vegfc mice, we stained bones from 35-day-old mice for TRAP
activity. This staining revealed that there were significantly more osteoclasts on the surface of corti-
cal bone in Osx-tTA;TetO-Vegfc mice than in Osx-tTA mice (Figure 3). To extend this finding, we
also measured the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) in Osx-tTA
and Osx-tTA;TetO-Vegfc mice. CTX-1 is a small peptide generated by osteoclast-mediated cleavage
of collagen I (Garnero et al., 2003). Importantly, CTX-1 was significantly higher in Osx-tTA;TetO-
Vegfc mice than Osx-tTA mice (Figure 3). Together, these data show that the number and activity of
osteoclasts are increased in Osx-tTA;TetO-Vegfc mice.
Zoledronic acid (also known as Zometa) is a drug that accumulates in bone and prevents bone
resorption by inhibiting farnesyl pyrophosphate synthase activity in osteoclasts (Clézardin, 2013). To
determine whether osteoclasts promote bone resorption in Osx-tTA;TetO-Vegfc mice, we treated
21-day-old mice with either vehicle or zoledronic acid for 2 weeks. The density of bone lymphatics
was not significantly different between zoledronic acid-treated and vehicle-treated Osx-tTA;TetO-
Vegfc mice (Figure 4). However, the number of osteoclasts and porosity of femurs were significantly
lower in zoledronic acid-treated mice than vehicle-treated mice (Figure 4). These data indicate that
bone loss in Osx-tTA;TetO-Vegfc mice is driven by osteoclasts.
To determine whether inhibition of lymphangiogenesis could prevent osteoclastogenesis and
bone loss in Osx-tTA;TetO-Vegfc mice, we analyzed femurs from vehicle and mF4-31C1-treated
mice. We focused our analysis on mF4-31C1-treated mice because these mice do not develop bone
lymphatics (Figure 2). We found that femurs from mF4-31C1-treated mice had significantly fewer
osteoclasts than femurs from vehicle-treated mice (Figure 5). Additionally, we found that femurs
from mF4-31C1-treated mice were significantly less porous than femurs from vehicle-treated mice
(Figure 5). These data show that inhibition of lymphangiogenesis can prevent osteoclastogenesis
and bone loss in Osx-tTA;TetO-Vegfc mice.
Inhibition of VEGF-C expression reverses the mutant phenotype of
Osx-tTA;TetO-Vegfc mice
Next, we set out to determine whether the mutant phenotype of Osx-tTA;TetO-Vegfc mice was
reversible. We first characterized the reversibility of VEGF-C expression in Osx-tTA;TetO-Vegfc
mice. We collected RNA from tibias from Osx-tTA mice, Osx-tTA;TetO-Vegfc mice that received nor-
mal water from E18.5 to P35, and Osx-tTA;TetO-Vegfc mice that received normal water from E18.5
to P35 and then doxycycline water for either 3 or 7 days (Figure 6). The expression of VEGF-C
mRNA was then evaluated by qPCR. VEGF-C mRNA levels were approximately 350-fold higher in
Osx-tTA;TetO-Vegfc mice than Osx-tTA mice. Importantly, VEGF-C mRNA levels in Osx-tTA;TetO-
Vegfc mice returned to normal within 3 days of being placed back on doxycycline water (Figure 6).
These data indicate that doxycycline rapidly inhibits the expression of VEGF-C in Osx-tTA;TetO-
Vegfc mice.
Figure 1 continued
(0 ± 0.0; n = 5), and P35 (0 ± 0.0; n = 6) Osx-tTA mice and in P21 (0 ± 0.0; n = 4), P28 (67 ± 22.06; n = 4), and P35 (130.3 ± 44.35; n = 4) Osx-tTA;TetO-
Vegfc mice. (J–O) Representative images of trabecular bone in Osx-tTA and Osx-tTA;TetO-Vegfc femurs. Sections were stained with an anti-podoplanin
antibody. Arrowheads point to podoplanin-positive osteocytes. Arrow points to podoplanin-positive lymphatics. (P) Graph showing lymphatic vessel
index values for trabecular bone in P21 (0 ± 0.0; n = 3), P28 (0 ± 0.0; n = 5), and P35 (0 ± 0.0; n = 6) Osx-tTA mice and P21 (0 ± 0.0; n = 4), P28
(0.167 ± 0.4082; n = 6), and P35 (189.5 ± 47.7; n = 4) Osx-tTA;TetO-Vegfc mice. (***p<0.001, ****p<0.0001, unpaired student’s T-test). ND = Not
Detected.
DOI: https://doi.org/10.7554/eLife.34323.002
The following figure supplements are available for figure 1:
Figure supplement 1. Expression pattern of GFP in Osx-tTA-TetO-tTA-Cre::GFP mice.
DOI: https://doi.org/10.7554/eLife.34323.003
Figure supplement 2. Expression of VEGF-C during embryonic development causes embryonic lethality.
DOI: https://doi.org/10.7554/eLife.34323.004
Figure supplement 3. Bone lymphatics express Lyve-1.
DOI: https://doi.org/10.7554/eLife.34323.005
Figure supplement 4. Lymphatics in soft tissues in Osx-tTA;TetO-Vegfc mice appear normal.
DOI: https://doi.org/10.7554/eLife.34323.006
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Figure 2. VEGFR3 signaling promotes the formation of bone lymphatics. (A) Schematic showing when mice received normal water and doxycycline
water. Osx-tTA;TetO-Vegfc mice were treated (3x/week) with vehicle, DC101 (VEGFR2 function-blocking antibody), or mF4-31C1 (VEGFR3 function-
blocking antibody) from P21 to P35. (B) Graph showing lymphatic index values for vehicle-treated (182.6 ± 61.56; n = 7), DC101-treated (99 ± 41.68;
n = 7), and mF4-31C1-treated mice (0 ± 0.0; n = 5). (**p<0.01, ****p<0.0001, ANOVA followed by Dunnett’s multiple comparisons test. Values were
tested against values for vehicle-treated mice). (C–E) Representative images of femurs stained with an anti-podoplanin antibody. The femurs are from
P35 mice. Arrows in panel E point to podoplanin-positive osteocytes. (F) Representative image of a femur from an Osx-tTA;TetO-Vegfd mouse that was
stained with an anti-podoplanin antibody. Arrows point to podoplanin-positive lymphatics in the bone marrow. (G) Graph showing lymphatic vessel
index values for trabecular bone in P35 Osx-tTA mice (0 ± 0; n = 6), Osx-tTA;TetO-Vegfc mice (189.5 ± 47.7; n = 4), and Osx-tTA;TetO-Vegfd mice
Figure 2 continued on next page
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To assess the reversibility of the lymphatic phenotype of Osx-tTA;TetO-Vegfc mice, we analyzed
ribs from Osx-tTA mice, Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35,
and Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35 and then doxycycline
water for either 3, 7, 28, or 56 days (Figure 6). Osx-tTA mice did not have lymphatic vessels in their
ribs and possessed a sparse network of lymphatics in their periosseous muscle (Figure 6). In con-
trast, Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35 had numerous lym-
phatic vessels in their ribs and an expanded network of lymphatics in their periosseous muscle
(Figure 6). To our surprise, the abnormal lymphatic vessels in the ribs, but not in the periosseous
muscle, gradually disappeared in Osx-tTA;TetO-Vegfc mice that received doxycycline (Figure 6).
These data show that irregular lymphatic vessels in bone, but not in periosseous muscle, depend on
continued VEGF-C signaling for their existence.
We next set out to characterize the reversibility of the bone phenotype of Osx-tTA;TetO-Vegfc
mice. We X-rayed ribs from Osx-tTA mice, Osx-tTA;TetO-Vegfc mice that received normal water
from E18.5 to P35, and Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35 and
then doxycycline water for 28 days. Similar to what we observed for femurs (Figure 3—figure sup-
plement 1) ribs in Osx-tTA;TetO-Vegfc mice had a moth-eaten appearance (Figure 7). Amazingly,
inhibition of VEGF-C expression caused ribs in Osx-tTA;TetO-Vegfc mice to switch from a moth-
eaten appearance to a normal appearance (Figure 7). To further explore the effect of VEGF-C inhibi-
tion on bone structure in Osx-tTA;TetO-Vegfc mice, we evaluated cortical bone porosity in femur
sections. Doxycycline caused cortical bone porosity in Osx-tTA;TetO-Vegfc mice to revert back to
normal. We also found that the number of osteoclasts and the circulating levels of CTX-1 in Osx-tTA;
TetO-Vegfc mice returned to normal after exposure to doxycycline (Figure 7). Together, these data
show that the bone phenotype of Osx-tTA;TetO-Vegfc mice is reversible.
Osx-tTA;TetO-Vegfc mice develop chylothorax
Chylothorax is frequently observed in GSD patients with thoracic involvement and is the leading
cause of mortality of GSD patients (Ludwig et al., 2016). During the course of our experiments we
discovered that Osx-tTA;TetO-Vegfc mice die prematurely (Figure 8). When we examined moribund
Osx-tTA;TetO-Vegfc mice, we found that their chest cavity was filled with fluid. The color of this fluid
ranged from milky white to light pink. The triglyceride content of the fluid was greater than 110 mg/
dl, which indicated that the effusion fluid was chyle (Figure 8). Chyle is lymph rich in fat that flows
through the thoracic duct. To identify the route by which chyle escaped the thoracic duct in Osx-
tTA;TetO-Vegfc mice, we injected the mesenteric lymph node of 35-day-old mice with Evans blue
dye (EBD). EBD was confined to the thoracic duct in Osx-tTA mice. In contrast, EBD spilled from the
thoracic duct into lymphatics in the periosseous muscle in Osx-tTA;TetO-Vegfc mice. EBD appeared
to leak from the irregular lymphatics along the chest wall. These findings indicate that the lymphatics
that form in the periosseous muscle do not function properly.
Discussion
Patients with GSD have lymphatics in their bones and their bones gradually disappear. In this study,
we show that overexpression of VEGF-C by bone cells induces the formation of bone lymphatics and
bone loss. Taken together, our findings demonstrate that expression of VEGF-C in bone is sufficient
to induce the pathologic hallmarks of GSD in mice.
VEGF-C has been shown to promote lymphangiogenesis in several different pathological settings.
However, investigators have only recently started to examine VEGF-C levels in patients with GSD.
The circulating level of VEGF-C was found to be slightly elevated in 1 GSD patient (Brodszki et al.,
2011), but not in two other GSD patients (Brodszki et al., 2011; Baud et al., 2015). We found that
the local level, but not the circulating level, of VEGF-C was elevated in Osx-tTA;TetO-Vegfc mice. In
Figure 2 continued
(293 ± 37.24; n = 3). (****p<0.0001, ANOVA followed by Dunnett’s multiple comparisons test. Values were tested against values for Osx-tTA mice).
ND = Not Detected.
DOI: https://doi.org/10.7554/eLife.34323.007
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the future, patient samples could be used to determine whether VEGF-C is locally elevated in
affected tissues in GSD patients.
VEGF-C is a growth factor that promotes lymphangiogenesis in embryos and in adult tissues.
VEGF-C activates VEGFR2 and VEGFR3 (Joukov et al., 1996). However, VEGF-C has a greater
Figure 3. Osx-tTA;TetO-Vegfc mice have more porous bones and osteoclasts than Osx-tTA mice. (A,B) Representative mCT images of femurs from Osx-
tTA and Osx-tTA;TetO-Vegfc mice. (C) Graph showing cortical bone porosity for femurs from Osx-TA (0.062 ± 0.0292, n = 5) and Osx-tTA;TetO-Vegfc
(0.209 ± 0.0204, n = 6) mice. (D,E) Representative mCT images of ribs from Osx-tTA and Osx-tTA;TetO-Vegfc mice. (F) Graph showing cortical bone
porosity for ribs from Osx-TA (0.024 ± 0.00293, n = 4) and Osx-tTA;TetO-Vegfc (0.165 ± 0.0265, n = 4) mice. (G) Graph showing results from the three-
point bending assay. Less force was required to break bones from Osx-TA;TetO-Vegfc mice (5.96 ± 1.404, n = 11) than Osx-tTA mice (9.231 ± 1.355,
n = 9) mice. (H,I) Representative images of TRAP-stained femurs from Osx-tTA and Osx-tTA;TetO-Vegfc mice. (J) Graph showing the number of
osteoclasts per mm of bone for Osx-tTA (1.18 ± 0.6818; n = 4) and Osx-tTA;TetO-Vegfc (6.84 ± 1.413; n = 4) mice. (K) Graph showing CTX-1 values for
Osx-tTA (1.7 ± 2.045; n = 8) and Osx-tTA;TetO-Vegfc (53.3 ± 31.8; n = 7) mice. (***p<0.001, ****p<0.0001, unpaired student’s T-test).
DOI: https://doi.org/10.7554/eLife.34323.008
The following figure supplements are available for figure 3:
Figure supplement 1. Bones from Osx-tTA;TetO-Vegfc mice have a moth-eaten appearance.
DOI: https://doi.org/10.7554/eLife.34323.009
Figure supplement 2. LECs do not degrade a calcium-phosphate matrix.
DOI: https://doi.org/10.7554/eLife.34323.010
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Figure 4. Zoledronic acid attenuates bone loss in Osx-tTA;TetO-Vegfc mice. (A) Schematic showing when mice received normal water and doxycycline
water. Osx-tTA;TetO-Vegfc mice were treated (q.a.d.) with vehicle or zoledronic acid from P21 to P35. (B,C) Representative images of femurs stained
with an anti-podoplanin antibody. (D) Graph showing lymphatic vessel index values for vehicle-treated (171.5 ± 18.18, n = 3) and zoledronic acid-treated
(165.2 ± 18.04, n = 5) mice. (E,F) Representative images of TRAP stained femurs from vehicle-treated and zoledronic acid-treated mice. (G) Graph
showing the number of osteoclasts per mm of bone for vehicle-treated (7.0 ± 3.15, n = 3) and zoledronic acid-treated (1.9 ± 1.9, n = 5) mice. (H,I)
Representative images of H and E stained femurs from vehicle-treated and zoledronic acid-treated mice. (J) Graph showing cortical bone porosity of
femurs for vehicle-treated (0.092 ± 0.0245, n = 3) and zoledronic acid-treated (0.030 ± 0.0103, n = 5) mice. (*p<0.05, **p<0.01, unpaired student’s
T-test).
DOI: https://doi.org/10.7554/eLife.34323.011
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affinity for VEGFR3 than VEGFR2 (Joukov et al., 1997). We found that mF4-31C1 (VEGFR3 inhibitor)
was more effective at inhibiting lymphangiogenesis in Osx-tTA;TetO-Vegfc mice than DC101
(VEGFR2 inhibitor). Our findings are consistent with other studies that have reported that blockade
or loss of VEGFR3 has a greater effect on lymphangiogenesis than blockade or loss of VEGFR2
(Yao et al., 2014; Zarkada et al., 2015; Baluk et al., 2005; Yuen et al., 2011).
LECs arise from multiple different sources. LECs come from pre-existing LECs (Srinivasan et al.,
2007), blood endothelial cells (BECs) (Srinivasan et al., 2007; Stanczuk et al., 2015; Martinez-
Figure 5. mF4-31C1 inhibits osteoclast formation and bone loss in Osx-tTA;TetO-Vegfc mice. (A) Schematic showing when mice received normal water
and doxycycline water. Osx-tTA;TetO-Vegfc mice were treated (3x/week) with vehicle or mF4-31C1 (VEGFR3 function-blocking antibody) from P21 to
P35. (B,C) Representative images of TRAP stained femurs from vehicle-treated and mF4-31C1-treated mice. (D) Graph showing the number of
osteoclasts per mm of bone for vehicle-treated (7.37 ± 2.088, n = 5) and mF4-31C1-treated (2.552 ± 0.6893, n = 5) mice. (E,F) Representative images of
H and E stained femurs from vehicle-treated and mF4-31C1-treated mice. (G) Graph showing cortical bone porosity of femurs for vehicle-treated
(0.07244 ± 0.02468, n = 5) and mF4-31C1-treated (0.006375 ± 0.007087, n = 4) mice. (**p<0.01, unpaired student’s T-test).
DOI: https://doi.org/10.7554/eLife.34323.012
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Figure 6. Bone lymphatics in Osx-tTA;TetO-Vegfc mice disappear following the withdrawal of VEGF-C. (A) Schematic showing when mice received
normal water and doxycycline water. One cohort of Osx-tTA;TetO-Vegfc mice received normal water from E18.5 to P35 (On 35d). A second cohort of
Osx-tTA;TetO-Vegfc mice received normal water from E18.5 to P35 and then doxycycline water from P35 to P38 (On 35d/Off 3d). A third cohort of Osx-
tTA;TetO-Vegfc mice received normal water from E18.5 to P35 and then doxycycline water from P35 to P42 (On 35d/Off 7d). (B) Graph showing the
relative VEGF-C mRNA levels in tibias from mice. (C) Schematic showing when mice received normal water and doxycycline water. Osx-tTA;TetO-Vegfc
mice received normal water from E18.5 to P35 (On 35d) or normal water from E18.5 to P35 and then doxycycline water for 3 (On 35d/Off 3d), 7 (On 35d/
Off 7d), 28 (On 35d/Off 28d), or 56 days (On 35d/Off 56d). (D–I) Representative images of ribs stained with an anti-podoplanin antibody. The dashed
lines separate the bone from the periosseous muscle. (J) Graph showing lymphatic vessel index values for ribs in Osx-tTA mice (0 ± 0.0; n = 5), Osx-tTA;
TetO-Vegfc mice that received normal water for 35 days (152.5 ± 29.56; n = 5), and Osx-tTA;TetO-Vegfc mice that received normal water for 35 days
and then doxycycline water for 3 (62.25 ± 51.7; n = 4), 7 (24.08 ± 21.26; n = 4), 28 (0 ± 0.0; n = 5) or 56 (0 ± 0.0; n = 3) days. (K) Graph showing lymphatic
vessel index values for periosseous muscle in Osx-tTA mice (3.61 ± 1.974; n = 5), Osx-tTA;TetO-Vegfc mice that received normal water for 35 days
(92.45 ± 34.63; n = 5), and Osx-tTA;TetO-Vegfc mice that received normal water for 35 days and then doxycycline water for 3 (99.29 ± 23.37; n = 4), 7
Figure 6 continued on next page
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Corral et al., 2015), and from an unknown cellular source (Martinez-Corral et al., 2015). There is
growing evidence that bone marrow-derived cells can also differentiate into LECs. Bone marrow
transplantation experiments with GFP-positive donor mice suggest that bone-marrow-derived cells
can incorporate into lymphatic vessels (Religa et al., 2005; Jiang et al., 2008). Additionally, mesen-
chymal stem cells isolated from bone are reported to express lymphatic markers such as Prox1 and
Lyve-1 following exposure to VEGF-C (Lee et al., 2010). The origin of bone LECs is not known. Line-
age-tracing studies with Osx-tTA;TetO-Vegfc mice could reveal whether LECs in bone arise from
pre-existing LECs, BECs, or from a different cellular source.
We found that Osx-tTA;TetO-Vegfc mice had more osteoclasts than Osx-tTA mice. There are con-
flicting reports as to whether or not VEGF-C can directly stimulate osteoclast formation. VEGF-C
was reported to promote osteoclast formation by one group (Motokawa et al., 2013) but not by
another (Zhang et al., 2008). We found that VEGF-C did not induce or enhance osteoclast formation
by RAW264.7 cells (data not shown). We also found that osteoclasts did not express VEGFR2 or
VEGFR3 in vivo (data not shown). Therefore, other factors are likely responsible for stimulating oste-
oclast formation in Osx-tTA;TetO-Vegfc mice. Macrophage colony-stimulating factor (M-CSF) is a
factor that promotes the development of osteoclasts (Dai et al., 2002). It was recently reported that
LECs express a high level of M-CSF and that LEC-conditioned media can stimulate osteoclast forma-
tion (Wang et al., 2017a2017). Importantly, an M-CSF function-blocking antibody inhibited the abil-
ity of LEC-conditioned media to promote osteoclast formation (Wang et al., 2017b). Therefore,
LECs in the bones of Osx-tTA;TetO-Vegfc mice may stimulate osteoclast development by secreting
M-CSF.
The precise cause of bone loss in GSD is unclear. A prevailing view in the field is that osteoclasts
promote excessive bone resorption in GSD. Osteoclasts have been detected in many different GSD
patient samples (Pazzaglia et al., 1997; Avelar et al., 2010; Bruder et al., 2009; Choma et al.,
1987; Hammer et al., 2005; Hirayama et al., 2001; Lehmann et al., 2009; Möller et al., 1999;
Silva, 2011; Spieth et al., 1997; Poirier, 1968; Jones et al., 1958) and CTX-1 has been reported to
be elevated in several patients (Liu et al., 2016). Zoledronic acid has been given to GSD patients in
an attempt to prevent bone loss (Avelar et al., 2010; Hagendoorn et al., 2006; Kuriyama et al.,
2010; Leite et al., 2013; Ruggieri et al., 2011; Gem et al., 2014; Mignogna et al., 2005;
Yerganyan et al., 2015). Indeed, several case reports state that there is no further progression of
the disease after the patient is treated with zoledronic acid (Avelar et al., 2010; Kuriyama et al.,
2010; Gem et al., 2014; Mignogna et al., 2005; Yerganyan et al., 2015). However, it is difficult to
assess the benefit of zoledronic acid in GSD patients because it is often given in combination with
other treatments and it is usually unclear as to whether the osteolytic process was active or inactive
at the start of treatment. We found that zoledronic acid attenuated bone loss in Osx-tTA;TetO-Vegfc
mice. These data indicate that osteoclasts promote the destruction of bone in Osx-tTA;TetO-Vegfc
mice and warrant further investigation into the effects of osteoclast inhibitors on GSD.
Several studies have shown that newly formed lymphatic vessels persist following the withdrawal
of a growth-promoting stimulus. One study showed that abnormal lymphatic vessels persisted in the
airways of CCSP-rtTA;TetO-Vegfc mice for up to 19 months after the withdrawal of VEGF-C
(Yao et al., 2014). Another study showed that abnormal lymphatic vessels persisted in the skin of
K14-rtTA;TetO-Vegfc mice for up to 6 months after the withdrawal of VEGF-C (Lohela et al., 2008).
Additionally, it was reported that global inactivation of VEGF-C in adult mice only caused lymphatic
vessels in the intestine to atrophy (Nurmi et al., 2015). Together, these findings suggest that lym-
phatic vessels in most tissues do not spontaneously regress following the withdrawal of VEGF-C. We
found that newly formed lymphatics in bone, but not in periosseous muscle, disappeared following
the withdrawal of VEGF-C. One possible explanation for this finding is that bone lacks lymphatic
maintenance factors. An alternative explanation for this finding is that bone possesses lymphatic
inhibitory factors whose effects can be overcome by overexpressing VEGF-C. Future experiments
Figure 6 continued
(74.84 ± 18.98; n = 4), 28 (92.67 ± 24.2; n = 5) or 56 (72.17 ± 14.05; n = 3) days. (**p<0.01, ***p<0.001, ****p<0.0001, ANOVA followed by Dunnett’s
multiple comparisons test. Values were tested against values for Osx-tTA mice). ND = Not Detected.
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Figure 7. The bone phenotype of Osx-tTA;TetO-Vegfc mice is reversible. (A–C) Representative x-ray images of femurs from Osx-tTA mice, Osx-tTA;
TetO-Vegfc mice that received normal water from E18.5 to P35 (On 35d), and Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35
and then doxycycline water from P35 to P63 (On 35d/Off 28d). Osx-tTA;TetO-Vegfc femurs switched from a moth-eaten appearance to a normal
appearance following exposure to doxycycline. (D) Graph showing cortical bone porosity values for femurs from Osx-tTA mice (0.011 ± 0.0103; n = 4),
Figure 7 continued on next page
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will help distinguish between these two possibilities and shed light on the molecular players and
pathways that control the patterning of the lymphatic vasculature.
Transgenic manipulation of the VEGF-C/VEGFR3 signaling pathway has been widely used to
investigate the role lymphatics serve in various pathological settings. Transgenic mice that express a
soluble version of VEGFR3 have been used to study the pathophysiology of lymphedema
(Mäkinen et al., 2001; Rutkowski et al., 2010), whereas VEGF-C transgenic mice have been used
to model pulmonary lymphangiectasia (Yao et al., 2014), to study the pathophysiology of chylo-
thorax (Nitschké et al., 2017), and to identify the specific function lymphatics serve in inflammation
(Huggenberger et al., 2011) and cancer (Mandriota et al., 2001; Hirakawa et al., 2007). We have
found that transgenic overexpression of VEGF-C in bone stimulates the formation of bone lym-
phatics and osteoclast-mediated bone resorption. Importantly, our transgenic mice can be used to
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Figure 7 continued
Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35 (0.149 ± 0.0615; n = 7), and Osx-tTA;TetO-Vegfc mice that received normal
water from E18.5 to P35 and then doxycycline water from P35 to P63 (0.014 ± 0.0152; n = 5). (E–G) Representative images of H and E stained femurs.
The femur from the Osx-tTA;TetO-Vegfc mouse that received normal water from E18.5 to P35 is filled with pores. (H) Graph showing the number of
osteoclasts per mm of bone for Osx-tTA mice (1.18. ±0.6818; n = 4), Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35
(6.84 ± 1.41; n = 4), and Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35 and then doxycycline water from P35 to P63
(1.45 ± 1.88; n = 4). (I) Graph showing CTX-1 values for Osx-tTA mice (1.7 ± 2.045; n = 8), Osx-tTA;TetO-Vegfc mice that received normal water from
E18.5 to P35 (53.3 ± 31.8; n = 7), and Osx-tTA;TetO-Vegfc mice that received normal water from E18.5 to P35 and then doxycycline water from P35 to
P63 (1.9 ± 1.19; n = 4). (***p<0.001, ANOVA followed by Dunnett’s multiple comparisons test. Values were tested against values for Osx-tTA mice.).
DOI: https://doi.org/10.7554/eLife.34323.014
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Mice and genotyping
The animal experiments described in this manuscript were carried out in accordance with an animal
protocol approved by the Institutional Animal Care and Use Committee of UT Southwestern Medical
Center. TetO-Vegfc mice (Lohela et al., 2008) were genotyped with the following primers: 50-
CCAAACCGGGCCCCTCTGCTAAC-30 and 50-ACTGTCCCCTGTCCTGGTATTGAG-30. The PCR
product for the transgenic allele was approximately 450 bp. TetO-Vegfd mice (Lammoglia et al.,
2016) were genotyped with the following primers: 5’-GCTCGTTTAGTGAACCGTCAG-3’ and 5’-TGC
TCGGATCTGTTGTTCAG-3’. The PCR product for the transgenic allele was approximately 250 bp.
Osx-tTA mice (Rodda and McMahon, 2006) were genotyped with the following primers: 50-CC
TGGAAAATGCTTCTGTCCG-30, 50-CAGGGTGTTATAAGCAATCCC-30, 50-CAATGGTAGGCTCACTC
TGGGAGATGAT 30, and 50- AACACACACTGGCAGGACTGGCTAGG-30. The wild-type band was
300 bp and the Cre band was 400 bp.
Doxycycline administration
Osx-tTA (control) and Osx-tTA;TetO-Vegfc littermates received water containing doxycycline (1 mg/
ml; Sigma-Aldrich, D9891, St. Louis, MO) and sucrose (5% w/v) from E0.5 to E18.5. Mice were then
placed on normal water. For the reversal experiments, Osx-tTA;TetO-Vegfc mice were placed back
on water containing doxycycline (1 mg/ml) and sucrose (5% w/v). Doxycycline water was replaced
three times a week.
Therapy studies with mice
DC101 and mF4-31C1 are rat monoclonal antibodies that block VEGFR2 and VEGFR3, respectively
(ImClone/Eli Lilly). P21 Osx-tTA;TetO-Vegfc mice were treated with sterile saline (3x/week; i.p.),
DC101 (800 mg; 3x/week; i.p.), or mF4-31C1 (800 mg; 3x/week; i.p.) for 2 weeks. To assess the effect
of osteoclast inhibition on bone loss, P21 Osx-tTA;TetO-Vegfc mice were treated with sterile saline
(q.a.d.; i.p.) or zoledronic acid (1.2 mg; q.a.d.; i.p.) for 2 weeks. Mice were randomly assigned to the
various treatment groups.
Immunohistochemistry
Slides were deparaffinized with xylene and rehydrated through a descending EtOH series. Endoge-
nous peroxidase activity was blocked by incubating slides with hydrogen peroxide diluted in metha-
nol. Antigen retrieval was performed by incubating slides in a proteinase K solution at 37˚C for 5
min. Slides were washed with PBS and then blocked for 1 hr with TBST (TBS +0.2% Tween 20)+20%
Aquablock. Tissue sections were incubated overnight with primary antibodies diluted in TBST +5%
BSA. The following primary antibodies were used for immunohistochemistry: goat anti-Lyve-1 (R and
D Systems; AF2125, Minneapolis, MN), chicken anti-GFP (Abcam; ab13970, Cambridge, MA), and
hamster anti-podoplanin (Abcam; ab11936). Slides were washed with TBST and then incubated with
HRP conjugated secondary antibodies diluted in TBST +5% BSA. Slides were washed with TBST and
antibody binding was detected with DAB (Dako, K3468, Santa Clara, CA).
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Measuring lymphatic vessel index
To quantify bone lymphatics, multiple pictures of cortical bone and of the area below the growth
plate were analyzed in ImageJ. A grid (19,000 cm2) was placed over the pictures and the number of
times that gridlines intersected within or on a lymphatic was determined.
Tartrate-resistant acid phosphatase (TRAP) staining and analysis
Bone sections were deparaffinized with xylene, rehydrated through a descending EtOH series, and
then placed in pre-warmed TRAP staining solution (TRAP basic incubation media + Fast Red Violet
Salt + Napthol AS-MX Phosphate) for 1 hr. Slides were rinsed with water and counterstained with
Fast Green for 30 s. Next, slides were rinsed with water, dehydrated through an ascending EtOH
series, and cleared in xylene. Pictures were taken with an AmScope FMA050 camera attached to a
Nikon Eclipse E600 microscope. The number of osteoclasts per mm bone surface was assessed with
ImageJ.
Figure 8. Osx-tTA;TetO-Vegfc mice develop chylothorax. (A) Survival curve for Osx-tTA and Osx-tTA;TetO-Vegfc mice (p<0.0001 Log-rank (Mantel-Cox)
test). (B) Graph showing triglyceride levels in effusion fluid collected from Osx-tTA;TetO-Vegfc mice (n = 4). The dashed line marks 110 mg/dl. (C)
Overview of the Evans blue dye (EBD) lymphangiography method. EBD injected into the mesenteric lymph node is transported to the thoracic duct. (D)
EBD is confined to the thoracic duct in Osx-tTA mice (n = 4). (E) In Osx-tTA;TetO-Vegfc mice, EBD spills from the thoracic duct into periosseous
lymphatics in muscle (n = 4).
DOI: https://doi.org/10.7554/eLife.34323.015
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ELISA for VEGF-C and CTX-1
Plasma was collected from mice and commercially available ELISA kits were used to measure the cir-
culating levels of VEGF-C (CUSABIO, #CSB-E07361M, Houston, TX) and CTX-1 (CUSABIO, #CSB-
E12782M). A BCA assay was performed to determine the total protein content of each plasma sam-
ple. VEGF-C and CTX-1 values were normalized to the total protein content.
RNA isolation and quantitative PCR
Frozen tibias were placed inside an RNase-free bag and crushed with a hammer. The crushed sam-
ples were transferred to a tube containing 1 ml of TRIzol (Life Technologies, 15596018, Carlsbad,
CA) and 1 ml of beads (Biospec Products, #11079124zx, Bartlesville, OK). The samples were homog-
enized in a Minibead Beater (Biospec Products). The homogenized lysate was transferred to a 2 ml
Phase Lock Gel Tube (Quanta, #2302830) and spun at 12,000 g for 5 min. The upper layer of the
spun solution was transferred to a Qiagen column and RNA was isolated with an RNeasy kit (Qiagen)
according to the manufacturer’s instructions. cDNA was synthesized with an iScript cDNA synthesis
kit (BioRad; #74104) according to the manufacturer’s instructions. The following primers were used
in SYBR green qPCR reactions to amplify Vegfc (5’-TCCCCTGTCCTGGTATTGAG-3’ and 5’-CGAGG
TCAAGGCTTTTGAAG-3’) and beta-actin (5’-CTGTCGAGTCGCGTCCA-3’ and 5’-ACCCA
TTCCCACCATCACAC-3’). Relative VEGF-C mRNA levels were calculated by the 2-DDCT method.
Evans blue dye lymphangiography
Our lymphangiography experiments were modeled after an approach recently published by
Nitschke and colleagues (Nitschké et al., 2017). Immediately after euthanasia, the mesenteric lymph
node was identified and injected with Evans blue dye (1% w/v). The thoracic cavity was then opened
and pictures of the thoracic duct and chest wall were captured with an AmScope FMA050 camera.
Assessment of cortical bone
Fixed bones were scanned using a mCT imaging system (35, Scanco Medical, Bassersdorf, Switzer-
land). The mCT Evaluation Program (V6.6) was used to measure the volume of the pores in bone and
the total volume of the region of interest. Cortical porosity was determined by dividing the total vol-
ume of the pores by the total volume of the region of interest. Cortical bone was also assessed his-
tologically. Decalcified bones were sectioned with a microtome and stained with hematoxylin and
eosin. Images were captured with an AmScope FMA050 camera attached to a Nikon Eclipse E600
microscope. ImageJ was used to measure the area of the pores in bone and the total area of the
region of interest. Cortical porosity was determined by dividing the total area of the pores by the
total area of the region of interest.
Three-point bending assay
Peak load at failure was tested in femora using a 3-point bending technique. Femora were placed
with the anterior aspect up so that an actuator contacted the bones at mid-diaphysis. A Test Resour-
ces DDL200 axial loading machine outfitted with an Interface SMT1-22 force transducer was set to a
cross-head displacement rate of 0.1 mm/sec. The femora rested on two supports 5 mm apart.
Osteo-assay surface plate
One ml of primary human LECs (50,000 cells/ml) and one ml of RAW264.7 cells (50,000 cells/ml)
were seeded into separate wells of an osteo-assay plate (Corning; #3987, Corning, NY). Recombi-
nant RANKL (final concentration 50 ng/ml) was added to the wells that contained RAW264.7 cells.
Cells were cultured at 37˚C for 72 hr. Media was aspirated and one ml of 10% bleach was added to
each well. Wells were then washed with water and images were captured with an inverted micro-
scope. Image J was used to measure the area resorbed by cells.
Statistical analysis
Data were analyzed using GraphPad Prism statistical analysis software (Version 7.0). All results are
expressed as mean ± SD. The number of mice in each group is indicated in the figure legends
(n = number of mice). For experiments with two groups, unpaired student’s T-tests were performed
to test means for significance. For experiments with more than two groups, differences were
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assessed by ANOVA followed by Dunnett’s multiple comparisons test. Data were considered signifi-
cant at p<0.05.
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Ylä-Herttuala S, Jackson DG, Alitalo K, McDonald DM. 2005. Pathogenesis of persistent lymphatic vessel
hyperplasia in chronic airway inflammation. Journal of Clinical Investigation 115:247–257. DOI: https://doi.org/
10.1172/JCI200522037, PMID: 15668734
Baud J, Lomri A, Graber D, Bikfalvi A. 2015. The therapeutic response in Gorham’s syndrome to the beta-
blocking agent propranolol is correlated to VEGF-A, but not to VEGF-C or FLT1 expression. BMC Research
Notes 8:333. DOI: https://doi.org/10.1186/s13104-015-1259-9, PMID: 26238450
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